Announcement • Apr 23
Sinocelltech Group Limited, Annual General Meeting, May 13, 2026 Sinocelltech Group Limited, Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: R and D Building, No. 31, Kechuang 7th Street, Economic and Technological Development Zone, Beijing China New Risk • Apr 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CN¥660m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥660m free cash flow). Negative equity (-CN¥55m). Announcement • Mar 30
Sinocelltech Group Limited to Report Q1, 2026 Results on Apr 30, 2026 Sinocelltech Group Limited announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥1.29 loss per share (down from CN¥0.24 profit in FY 2024). Revenue: CN¥1.56b (down 38% from FY 2024). Net loss: CN¥553.3m (down CN¥665.2m from profit in FY 2024). Revenue missed analyst estimates by 46%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Dec 26
Sinocelltech Group Limited to Report Fiscal Year 2025 Results on Apr 23, 2026 Sinocelltech Group Limited announced that they will report fiscal year 2025 results on Apr 23, 2026 Buy Or Sell Opportunity • Nov 25
Now 20% overvalued Over the last 90 days, the stock has fallen 27% to CN¥47.50. The fair value is estimated to be CN¥39.48, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 72%. Reported Earnings • Oct 31
Third quarter 2025 earnings released: CN¥0.38 loss per share (vs CN¥0.057 profit in 3Q 2024) Third quarter 2025 results: CN¥0.38 loss per share (down from CN¥0.057 profit in 3Q 2024). Revenue: CN¥339.9m (down 46% from 3Q 2024). Net loss: CN¥216.9m (down CN¥241.1m from profit in 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Sinocelltech Group Limited to Report Q3, 2025 Results on Oct 31, 2025 Sinocelltech Group Limited announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
Sinocelltech Group Limited to Report First Half, 2025 Results on Aug 29, 2025 Sinocelltech Group Limited announced that they will report first half, 2025 results on Aug 29, 2025 New Risk • Jun 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (25% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). Announcement • Jun 06
Sinocelltech Group Limited announced that it expects to receive CNY 900 million in funding from Lhasa Alike Investment Consulting Co., Ltd. Sinocelltech Group Limited announced that it has entered into a securities purchase agreement to issue not more than 25,000,000 shares at a price of CNY 36 per share for the gross proceeds of CNY 900,000,000 on June 5, 2025. The transaction will include participation from Lhasa Alike Investment Consulting Co., Ltd. The transaction has been approved by the shareholders of the company in the third board of directors of the company. The transaction is subjected to approval of the company's shareholders' meeting, approval of the Shanghai Stock Exchange, approval of the Shanghai Stock Exchange. New Risk • May 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 25% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (25% accrual ratio). Price Target Changed • May 08
Price target decreased by 20% to CN¥54.00 Down from CN¥67.50, the current price target is an average from 2 analysts. New target price is 47% above last closing price of CN¥36.85. Stock is down 27% over the past year. The company is forecast to post earnings per share of CN¥1.20 for next year compared to CN¥0.24 last year. Reported Earnings • Apr 26
First quarter 2025 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.13 (down from CN¥0.17 in 1Q 2024). Revenue: CN¥519.7m (down 15% from 1Q 2024). Net income: CN¥63.8m (down 14% from 1Q 2024). Profit margin: 12% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Apr 26
Sinocelltech Group Limited, Annual General Meeting, May 16, 2025 Sinocelltech Group Limited, Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: R and D Building, No. 31, Kechuang 7th Street, Economic and Technological Development Zone, Beijing China Announcement • Mar 28
Sinocelltech Group Limited to Report Q1, 2025 Results on Apr 26, 2025 Sinocelltech Group Limited announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Feb 25
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.25 (up from CN¥0.89 loss in FY 2023). Revenue: CN¥2.51b (up 33% from FY 2023). Net income: CN¥112.0m (up CN¥508.0m from FY 2023). Profit margin: 4.5% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 60%. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2025 The analyst covering Sinocelltech Group previously expected the company to break even in 2024. New forecast suggests the company will make a profit of CN¥533.0m in 2025. Average annual earnings growth of 139% is required to achieve expected profit on schedule. Announcement • Dec 27
Sinocelltech Group Limited to Report Fiscal Year 2024 Results on Apr 26, 2025 Sinocelltech Group Limited announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.057 (vs CN¥0.18 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.057 (up from CN¥0.18 loss in 3Q 2023). Revenue: CN¥632.3m (up 11% from 3Q 2023). Net income: CN¥24.2m (up CN¥106.4m from 3Q 2023). Profit margin: 3.8% (up from net loss in 3Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥389m free cash flow). Negative equity (-CN¥465m). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Announcement • Sep 30
Sinocelltech Group Limited to Report Q3, 2024 Results on Oct 29, 2024 Sinocelltech Group Limited announced that they will report Q3, 2024 results on Oct 29, 2024 Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.034 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.11 (up from CN¥0.034 in 2Q 2023). Revenue: CN¥692.2m (up 44% from 2Q 2023). Net income: CN¥51.5m (up 240% from 2Q 2023). Profit margin: 7.4% (up from 3.2% in 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Jun 29
Sinocelltech Group Limited to Report First Half, 2024 Results on Aug 22, 2024 Sinocelltech Group Limited announced that they will report first half, 2024 results on Aug 22, 2024 Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.34 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.34 loss in 1Q 2023). Revenue: CN¥612.5m (up 86% from 1Q 2023). Net income: CN¥74.2m (up CN¥227.2m from 1Q 2023). Profit margin: 12% (up from net loss in 1Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 18
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: CN¥0.89 loss per share (improved from CN¥1.19 loss in FY 2022). Revenue: CN¥1.89b (up 85% from FY 2022). Net loss: CN¥396.0m (loss narrowed 24% from FY 2022). Products in clinical trials Phase I: 1 Phase III: 3 Post-clinical trial products Pre-registration: 3 Approved (during full year): 2 Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Apr 13
Sinocelltech Group Limited, Annual General Meeting, May 07, 2024 Sinocelltech Group Limited, Annual General Meeting, May 07, 2024, at 14:30 China Standard Time. Announcement • Mar 29
Sinocelltech Group Limited to Report Q1, 2024 Results on Apr 26, 2024 Sinocelltech Group Limited announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 24
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: CN¥0.89 loss per share (improved from CN¥1.19 loss in FY 2022). Revenue: CN¥1.89b (up 85% from FY 2022). Net loss: CN¥396.0m (loss narrowed 24% from FY 2022). Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 158%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 06
Price target increased by 9.0% to CN¥79.00 Up from CN¥72.50, the current price target is an average from 2 analysts. New target price is 96% above last closing price of CN¥40.36. Stock is down 43% over the past year. The company is forecast to post a net loss per share of CN¥0.34 next year compared to a net loss per share of CN¥1.19 last year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.34 loss in 3Q 2022) Third quarter 2023 results: CN¥0.18 loss per share (improved from CN¥0.34 loss in 3Q 2022). Revenue: CN¥571.2m (up 108% from 3Q 2022). Net loss: CN¥82.1m (loss narrowed 46% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.034 (vs CN¥0.25 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.034 (up from CN¥0.25 loss in 2Q 2022). Revenue: CN¥479.3m (up 118% from 2Q 2022). Net income: CN¥15.2m (up CN¥122.2m from 2Q 2022). Profit margin: 3.2% (up from net loss in 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Wei He was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: CN¥1.99 loss per share (down from CN¥1.74 loss in FY 2020). Revenue: CN¥134.4m (up CN¥134.1m from FY 2020). Net loss: CN¥866.8m (loss widened 22% from FY 2020). Revenue was in line with analyst estimates. Reported Earnings • Oct 28
Third quarter 2021 earnings released: CN¥0.52 loss per share (vs CN¥0.40 loss in 3Q 2020) Third quarter 2021 results: Net loss: CN¥223.7m (loss widened 28% from 3Q 2020). Is New 90 Day High Low • Dec 16
New 90-day low: CN¥45.40 The company is down 25% from its price of CN¥60.78 on 17 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Announcement • Jul 10
Sinocelltech Group Limited to Report First Half, 2020 Results on Aug 28, 2020 Sinocelltech Group Limited announced that they will report first half, 2020 results on Aug 28, 2020